Cargando…

Myosin binding protein H-like (MYBPHL): a promising biomarker to predict atrial damage

Myosin binding protein H-like (MYBPHL) is a protein associated with myofilament structures in atrial tissue. The protein exists in two isoforms that share an identical amino acid sequence except for a deletion of 23 amino acids in isoform 2. In this study, MYBPHL was found to be expressed preferenti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lahm, Harald, Dreßen, Martina, Beck, Nicole, Doppler, Stefanie, Deutsch, Marcus-André, Matsushima, Shunsuke, Neb, Irina, König, Karl Christian, Sideris, Konstantinos, Voss, Stefanie, Eschenbach, Lena, Puluca, Nazan, Deisenhofer, Isabel, Doll, Sophia, Holdenrieder, Stefan, Mann, Matthias, Lange, Rüdiger, Krane, Markus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6620353/
https://www.ncbi.nlm.nih.gov/pubmed/31292467
http://dx.doi.org/10.1038/s41598-019-46123-w
Descripción
Sumario:Myosin binding protein H-like (MYBPHL) is a protein associated with myofilament structures in atrial tissue. The protein exists in two isoforms that share an identical amino acid sequence except for a deletion of 23 amino acids in isoform 2. In this study, MYBPHL was found to be expressed preferentially in atrial tissue. The expression of isoform 2 was almost exclusively restricted to the atria and barely detectable in the ventricle, arteria mammaria interna, and skeletal muscle. After atrial damage induced by cryo- or radiofrequency ablation, MYBPHL was rapidly and specifically released into the peripheral circulation in a time-dependent manner. The plasma MYBPHL concentration remained substantially elevated up to 24 hours after the arrival of patients at the intensive care unit. In addition, the recorded MYBPHL values were strongly correlated with those of the established biomarker CK-MB. In contrast, an increase in MYBPHL levels was not evident in patients undergoing aortic valve replacement or transcatheter aortic valve implantation. In these patients, the values remained virtually constant and never exceeded the concentration in the plasma of healthy controls. Our findings suggest that MYBPHL can be used as a precise and reliable biomarker to specifically predict atrial myocardial damage.